March 22, 2018 / 6:13 PM / 6 months ago

BRIEF-Oncology Venture Sweden Announce Positive Study Results For Diagnostic Tool DRP® In Lung Cancer Patients Treated With Cisplatin​

March 22 (Reuters) - Oncology Venture Sweden Ab:

* ONCOLOGY VENTURE SWEDEN, MEDICAL PROGNOSIS INSTITUTE ANNOUNCE POSITIVE STUDY RESULTS FOR DIAGNOSTIC TOOL DRP® IN LUNG CANCER PATIENTS TREATED WITH CISPLATIN​

* ‍PATIENTS THAT WERE ASSESSED AS MOST LIKELY TREATMENT RESPONDERS BASED ON A DRP® EVALUATION HAD A MORE THAN THREE TIMES HIGHER SURVIVAL RATE COMPARED TO PATIENTS ASSESSED AS LESS LIKELY TO RESPOND​

* ‍RESULTS SHOW THAT DRP® CAN FACILITATE FURTHER DEVELOPMENT AND FUTURE POTENTIAL USE OF ONCOLOGY VENTURES CISPLATIN-BASED DRUG CANDIDATE LIPLACIS®​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below